Is thymosin beta 15A ( TMSB15A ) a predictor of chemotherapy response in triple-negative breast cancer?
In TNBC, TMSB15A gene expression analysis might help to select patients with a high chance for pCR after NACT.
Here, we identify high FGFR1 expression as a candidate prognostic biomarker in HPV-negative HNSCC. Furthermore, we provide a rationale for treating FGFR1-expressing HNSCC with the FGFR inhibitor AZD4547 and for combining AZD4547 and gefitinib in FGFR inhibitor-resistant HNSCC patients. Clin Cancer Res; 22(15); 3884-93. ©2016 AACR.